drugset / Trial / NCT03103295

3D Tissue Engineered Bone Equivalent for Treatment of Traumatic Bone Defects

NCT03103295 ↗

Phase 1/2 Unknown 20 enrolled A.A. Partners, LLC
NaSingle-groupOpen-labelTreatment

Summary

This study investigates safety and efficacy of traumatic bone defects treatment with use of 3D tissue engineered bone equivalent (3D-TEBE). The aim of this study is to evaluate 3D-TEBE transplantation as a safe and efficient treatment for patients with traumatic long bone defects of critical size.

Timeline

Start
2015-11-20
Primary completion
2018-12-20
Completion
2018-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject 3D-Tissue Engineered Bone Equivalent Cell therapy — —